1225430-36-3Relevant articles and documents
Synthesis and biological evaluation of novel C-aryl D-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors
Lin, Tzung-Sheng,Liw, Ya-Wen,Song, Jen-Shin,Hsieh, Tsung-Chih,Yeh, Hsien-Wei,Hsu, Lih-Ching,Lin, Chun-Jung,Wu, Szu-Huei,Liang, Pi-Hui
, p. 6282 - 6291 (2013/10/22)
Novel C-aryl-d-glucofuranosides were synthesized and evaluated for their capacity to inhibit human sodium-dependent glucose co-transporter 2 (hSGLT2) and hSGLT1. Compound 21q demonstrated the best in vitro inhibitory activity against SGLT2 in this series (EC50 = 0.62 μM).
NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
-
Page/Page column 51, (2010/12/31)
A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.
Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners
Kim, Min Ju,Lee, Junwon,Kang, Suk Youn,Lee, Sung-Han,Son, Eun-Jung,Jung, Myung Eun,Lee, Suk Ho,Song, Kwang-Seop,Lee, MinWoo,Han, Ho-Kyun,Kim, Jeongmin,Lee, Jinhwa
supporting information; scheme or table, p. 3420 - 3425 (2010/08/07)
Novel C-aryl glucoside SGLT2 inhibitors containing pyridazine motif were designed and synthesized for biological evaluation. Among the compounds tested, pyridazine containing methylthio moiety 22l or thiadiazole ring 22ah showed the best in vitro inhibitory activities in this series (IC50 = 13.4, 11.4 nM, respectively) against SGLT2 to date. Subsequently, compound 22l exhibited reasonable urinary glucose excretion and glucosuria in normal SD rats, thereby demonstrating that this pyridazine series possesses both in vitro SGLT2 inhibition and in vivo efficacy, albeit to a lower degree.